RFG
FBRX icon

REAP Financial Group’s Forte Biosciences FBRX Stock Holding History

REAP Financial Group’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64 Hold
3
– – ﹤0.01% 534
2026
Q1 		$78 Hold
3
– – ﹤0.01% 523
2025
Q4 		$82 Hold
3
– – ﹤0.01% 537
2025
Q3 		$45 Hold
3
– – ﹤0.01% 510
2025
Q2 		$39 Hold
3
– – ﹤0.01% 493
2025
Q1 		$23 Hold
3
– – ﹤0.01% 534
2024
Q4 		$68 Hold
3
– – ﹤0.01% 593
2024
Q3 		$17 Sell
3
-1
-25% -$10 ﹤0.01% 584
2024
Q2 		$52 Hold
4
– – ﹤0.01% 540
2024
Q1 		$68 Hold
4
– – ﹤0.01% 581
2023
Q4 		$80 Buy
+4
New +$56 ﹤0.01% 647

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

REAP Financial Group's FBRX Position: Q2 2026 in Review

REAP Financial Group held its Forte Biosciences (FBRX) position steady in Q2 2026 at 3 shares worth $64. The position accounts for ﹤0.01% of the portfolio, ranked #534.

REAP Financial Group first reported a position in FBRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $82 in Q4 2025. 57 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • REAP Financial Group held 3 shares of Forte Biosciences worth $64 as of Q2 2026.
  • REAP Financial Group left its Forte Biosciences share count unchanged in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of REAP Financial Group's portfolio in Q2 2026, its #534 holding.
  • REAP Financial Group first reported a position in Forte Biosciences in Q4 2023 and has held it in 11 quarters since.
  • REAP Financial Group's Forte Biosciences position peaked at $82 in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on REAP Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.